Akela’s subsidiary PharmaForm signs development agreement
Under the terms of the agreement, PharmaForm will develop products in one or more therapeutic areas utilizing PharmaForm’s core expertise in hot melt extrusion. In addition to providing
Health innovation platform developer Aditxt and its fully owned subsidiary Ignite Proteomics have announced their plans for a business combination with a strategic partner that values the latter at an implied equity value of nearly $150m.